Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

NCT ID: NCT05046899

Last Updated: 2022-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-14

Study Completion Date

2022-06-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed about the investigation and the potential risks, all subjects giving written informed consent will undergo screening to determine eligibility for study entry. At week 0, subjects who meet the eligibility requirements will be randomised in open, intra-patient investigation, treated with BIOpH+ Psoriasis Medical Bath on one side, and comparative treatment on the other side for 8 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Intra-patient design.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BIOpH+ Psoriasis Medical Bath

BIOpH+ Psoriasis Medical Bath is bath. Each bath will take 20 minutes and number of bath during the entire study period is approximately 35 baths.

Group Type EXPERIMENTAL

BIOpH+ Psoriasis Medical Bath

Intervention Type DEVICE

20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.

Comparative device

Comparative device is Cetaphil Moisturizing Lotion. The lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.

Group Type ACTIVE_COMPARATOR

Cetaphil Moisturizing Lotion

Intervention Type DEVICE

Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIOpH+ Psoriasis Medical Bath

20 min bath every day during 1 week and thereafter 20 min bath every second day for additional 7 weeks.

Intervention Type DEVICE

Cetaphil Moisturizing Lotion

Cetaphil Moisturizing Lotion will be applied on the affected body area on the same days as the BIOpH+ Psoriasis Medical Bath is performed.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntary agreed to participation and has duly signed Informed Consent Form
* Males and females ≥ 18 years of age
* In the Investigator's opinion, the patient is not likely to become pregnant during study participation (e.g. in a same-sex relationship, not sexually active, sterile, not of child-bearing age, uses contraception, etc.)
* Subject diagnosed with stable mild-moderate plaque psoriasis, defined by PASI ≤ 9
* Intra-individual difference between left and right hemi-body PASI scores not \> 1.0
* Patients with symmetrical psoriasis

Exclusion Criteria

* Presence of other forms of psoriasis other than psoriasis vulgaris (palmoplantar psoriasis, inverse psoriasis, other forms of hyperkeratosis)
* Use of systemic/biological treatment for psoriasis
* Known hypersensitivity or allergy to study products
* Any serious medical condition that could interfere with the evaluation of study results
* Poor compliance in other investigational study, as assessed by investigator
* Pregnant, breastfeeding, or planning to become pregnant during study
* Patients with alcohol -or drug abuse
* Any other conditions as judged by the investigator may make the follow-up or investigation inappropriate
* Anyone unsuitable to participate as subject according to the Declaration of Helsinki
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biocool AB

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Lundvall, MD

Role: PRINCIPAL_INVESTIGATOR

Research Unit, University Hospital Örebro, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Avdelningen för klinisk prövning

Örebro, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BioC002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.